SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lyka Labs - Quaterly Results

20 Jan 2022 Evaluate
A decent increase of about 49.02% in the sales to Rs. 281.82 millions was observed for the quarter ended December 2021. The sales figure stood at Rs. 189.12 millions during the year-ago period.The Total Profit for the quarter ended December 2021 of Rs. 56.79 millions grew from Rs.-30.65 millionsOP of the company witnessed a marginal growth to 125.96 millions from 50.02 millions in the same quarter last year.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202112 202012 % Var 202112 202012 % Var 202103 202003 % Var
Sales 281.82 189.12 49.02 1366.66 443.55 208.12 622.63 407.43 52.82
Other Income 6.73 3.96 69.95 20.60 13.02 58.22 22.10 25.96 -14.87
PBIDT 125.96 50.02 151.82 879.96 103.27 752.10 166.35 -6.20 -2783.06
Interest 45.95 65.26 -29.59 170.12 192.48 -11.62 255.53 190.12 34.40
PBDT 81.79 -11.66 -801.46 691.19 -86.54 -898.69 -103.47 -473.85 -78.16
Depreciation 21.18 20.47 3.47 62.58 60.99 2.61 80.50 77.67 3.64
PBT 60.61 -32.13 -288.64 628.61 -147.53 -526.09 -183.97 -551.52 -66.64
TAX 3.82 -1.48 -358.11 77.25 -0.60 -12975.00 -39.36 2.35 -1774.89
Deferred Tax 3.82 -1.48 -358.11 77.25 -0.60 -12975.00 -39.36 2.35 -1774.89
PAT 56.79 -30.65 -285.29 551.36 -146.93 -475.25 -144.61 -553.87 -73.89
Equity 286.90 286.90 0.00 286.90 286.90 0.00 286.90 286.90 0.00
PBIDTM(%) 44.70 26.45 68.99 64.39 23.28 176.55 26.72 -1.52 -1855.75

Lyka Labs Share Price

72.70 3.46 (5.00%)
07-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1903.00
Dr. Reddys Labs. 1353.75
Cipla 1452.35
Zydus Lifesciences 1152.90
Lupin 2489.85
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: